3.18

0.63% -0.02

Anixa Biosciences Inc (ANIX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Anixa Biosciences Inc stock is traded at $3.18, with a volume of 107.79K. It is down -0.63% in the last 24 hours and down -0.31% over the past month. Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Previous Close:

$3.20

Open:

$3.2

24h Volume:

107.79K

Relative Volume:

0.50

Market Cap:

$108.19M

Revenue:

$210.00K

Net Income/Loss:

$-10.12M

P/E Ratio:

-10.49

EPS:

-0.3032

Net Cash Flow:

$-7.12M

1W Performance:

-7.02%

1M Performance:

-0.31%

6M Performance:

+12.77%

1Y Performance:

+7.07%

1-Day Range:

$3.10

$3.2306

1-Week Range:

$3.10

$3.40

52-Week Range:

$2.32

$5.4566

Anixa Biosciences Inc Stock (ANIX) Company Profile

Name

Anixa Biosciences Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

408-708-9808

Address

3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE

Employee

Twitter

@anixabio

Next Earnings Date

2026-09-09

Latest SEC Filings

ANIX's Discussions on Twitter

Compare ANIX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIX Anixa Biosciences Inc	3.18	109.89M	210.00K	-10.12M	-7.12M	-0.3032
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-21-25	Initiated	Maxim Group	Buy
Dec-23-22	Initiated	Chardan Capital Markets	Buy
Apr-12-21	Initiated	H.C. Wainwright	Buy

Anixa Biosciences Inc Stock (ANIX) Latest News

Aug 03, 2026

Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Buys 5,000 Shares - MarketBeat

Aug 03, 2026

Anixa Biosciences (ANIX) CEO Amit Kumar Buys 5,000 Shares, Insider Ownership Climbs to 657,000 Shares - GuruFocus

Aug 03, 2026

Anixa Biosciences CEO Amit Kumar buys $17,350 in company stock By Investing.com - Investing.com Nigeria

Aug 03, 2026

Form 4 Anixa Biosciences Inc For: 3 August By Investing.com - Investing.com Nigeria

Aug 03, 2026

Anixa Biosciences (ANIX) CEO purchases 5,000 company shares - Stock Titan

Aug 03, 2026

Anixa Biosciences CEO Amit Kumar acquires 5,000 common shares valued at $17,350 - Bitget

Aug 03, 2026

Aug 01, 2026

Anixa Biosciences Inc (NASDAQ:ANIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 01, 2026

Jul 29, 2026

Form 4 Anixa Biosciences Inc For: 29 July By Investing.com - Investing.com Nigeria

Jul 29, 2026

Anixa Biosciences (ANIX) director exercises 6,000 options, uses 5,428 shares to pay cost - Stock Titan

Jul 29, 2026

Jul 28, 2026

Anixa Biosciences (NASDAQ:ANIX) CEO Acquires $17,200.00 in Stock - MarketBeat

Jul 28, 2026

Anixa Biosciences (NASDAQ:ANIX) CEO Acquires 3,000 Shares - MarketBeat

Jul 28, 2026

Anixa Biosciences (NASDAQ: ANIX) CEO buys 5,000 shares, now holds 652,000 - Stock Titan

Jul 28, 2026

Jul 27, 2026